Netupitant/palonosetron

Drug Profile

Netupitant/palonosetron

Alternative Names: Akynzeo; NEPA; NEPA - Helsinn; Netupitant-palonosetron fixed dose combination (NEPA); Palonosetron/netupitant

Latest Information Update: 14 Jun 2017

Price : $50

At a glance

  • Originator Helsinn
  • Developer Helsinn; Taiho Pharmaceutical; Vifor Pharma
  • Class Antiemetics; Isoquinolines; Pyridines; Quinuclidines; Small molecules
  • Mechanism of Action G protein-coupled receptor modulators; Neurokinin 1 antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 06 Jun 2017 Helsinn completes a phase III trial in Chemotherapy induced nausea and vomiting (Prevention) in South Korea (PO) prior to June 2017
  • 03 May 2017 Helsinn Healthcare initiates enrolment in a phase II/III trial in Chemotherapy induced nausea and vomiting (Prevention) in USA (PO, Capsule) (NCT03040726)
  • 15 Feb 2017 Netupitant/palonosetron licensed to Mundipharma in Iran, Pakistan, Indonesia, Argentina, Uruguay, Paraguay and 30 countries in Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top